Preemptive risk management is fundamental to any patient-centric supply chain – especially when it comes to highly personalized medicines like cell and gene therapies.
Fiona Geiger, Vice President of Client Services for Yourway, shares key insights to help advanced therapy developers navigate the complexities of the patient-centric supply chain to deliver these time and temperature-sensitive therapies to study participants and patients.
Read Article
Back to Index